MilliporeSigma News
- MilliporeSigma Introduces Comprehensive AAV Express Platform For Streamlined Gene Therapy Production 10/17/2025
- Simtra BioPharma Solutions And MilliporeSigma Announce Strategic Alliance For Antibody Drug Conjugates Drug Substance And Drug Product Manufacturing Services 6/12/2025
-
MilliporeSigma Invests $76 Million To Expand ADC Manufacturing For Novel Cancer Therapies
11/6/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced a $76 million expansion of its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri. This investment will triple existing capacity and enhance the company’s contract development and manufacturing organization (CDMO) offering, reinforcing its commitment to clients and patients.
-
MilliporeSigma Expands Its Optimized VirusExpress® Platform For Lentiviral Vectors, Further Enhancing Quality And De-Risking Cell And Gene Therapy Manufacturing
5/8/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, is pleased to announce the expansion of its VirusExpress® platform used in the development and manufacturing of lentiviral vectors.